Grifols (NASDAQ:GRFS) Shares Up 5.1% – Should You Buy?

Shares of Grifols, S.A. (NASDAQ:GRFS) rose 5.1% on Tuesday . The stock traded as high as $8.02 and last traded at $8.01. Approximately 514,452 shares were traded during trading, a decline of 72% from the average daily volume of 1,834,552 shares. The stock had previously closed at $7.62.

Wall Street Analyst Weigh In

Separately, Berenberg Bank upgraded shares of Grifols to a “strong-buy” rating in a research report on Tuesday, October 29th.

Grifols Stock Performance

The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. The business has a fifty day moving average of $8.43 and a 200 day moving average of $8.10.

Hedge Funds Weigh In On Grifols

A number of hedge funds have recently modified their holdings of GRFS. B. Riley Wealth Advisors Inc. acquired a new position in Grifols in the second quarter valued at about $359,000. Sei Investments Co. lifted its holdings in shares of Grifols by 4.7% in the 2nd quarter. Sei Investments Co. now owns 2,209,547 shares of the biotechnology company’s stock worth $13,931,000 after acquiring an additional 100,131 shares during the last quarter. Melqart Asset Management UK Ltd acquired a new position in shares of Grifols in the 3rd quarter worth approximately $1,628,000. Hantz Financial Services Inc. purchased a new position in shares of Grifols during the 2nd quarter worth approximately $1,235,000. Finally, Verition Fund Management LLC acquired a new stake in Grifols in the 3rd quarter valued at approximately $2,636,000.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.